Does testosterone substitution therapy influence the seriousness of BHP?

1. Dohle GR, Arver S, Bettocchi C, et al. Guidelines on male hypogonadism. Dostupný z http://uroweb.org/wp‑content/uploads/EAU‑Guidelines‑Male‑Hypogonadism-2015.pdf.

2. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late‑onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur. J. Endocrinol. 2008; 159(5): 507-514, Int J Impot Res. 2009; 21(1): 1-8, Int J Androl. 2009; 32(1): 1-10, Int J Androl. 2009; 32(1): 1-10, Aging Male. 2008: 1-8.

3. Rosen RC, Giuliano F, Carson CC. Sexual dysfunction and lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). Eur Urol. 2005; 47(6): 824-837.

4. Khera M, Crawford D, Morales A, et al. Testosterone and prostate cancer - a paradigm shift "Bye‑bye Androgen Hypothesis, Welcome Saturation Model". Eur Urol. 2014; 65(1):115-23, dostupné také z http://www.europeanurology.com/article/S0302-2838(13)00843-9/pdf.

5. Alonso‑Magdalena P, Brössner C, Reiner A, at al. A role for epithelial‑mesenchymal transition in the etiology of benign prostatic hyperplasia. Proc Natl Acad Sci USA. 2009; 106(8): 2859-2863.

6. Bravo G, Massa H, Rose'Meyer R, at al. Effect of shortterm androgen deficiency on bladder contractility and urothelial mediator release. Naunyn Schmiedebergs Arch Pharmacol. 2017; 11. Dostupné také z https://www.ncbi.nlm.nih.gov/pubmed/28190243.

7. Hammarsten J, Peeker R. Urological aspects of the metabolic syndrome. Nat Rev Urol. 2011; 8(9): 483-494. Dostupný také z http://www.medscape.com/viewarticle/750517_print.

8. Wang CH, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care, 2011; 34: 1669-1675.

9. Andersson KE, de Groat WC, McVary KT, et al. Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn. 2011; 30: 292-301.

10. Schmidt LJ, Duncan K, Yadav N, et al. RhoA as a mediator of clinically relevant androgen action in prostate cancer cells. Mol Endocrinol. 2012; 26(5): 716-735. Dostupné z http://www.ncbi.nlm.nih.gov/pubmed/22456196.

11. Kathrins M, Doersch K, Nimeh T, et al. The relationship between testosterone replacement therapy and lower urinary tract symptoms: a systematic review. Urology 2016; 88: 22-32, (ISSN 1527-9995), dostupný také z http://reference.medscape.com/medline/abstract/26616095?prt=true

12. Crawford ED, Poage W, Nyhuis A, Price DA, Dowsett SA, Muram D. Effects of Testosterone Level on Lower Urinary Tract Symptoms. Am J Mens Health. 2016; 10(5): 440-442. Dostupný také z http://reference.medscape.com/medline/abstract/26077271?prt=true.

13. Francomano D, Ilacqua A, Bruzziches R, Lenzi A, Aversa A. Effects of 5 year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrom. Urology. 2014; 83(1): 167-173. Dostupný také z http://reference.medscape.com/medline/abstract/24139347?prt=true.

14. Shim JS, Kim JH, Yoon YS, et al. Serum testosterone levels are negatively correlated with international prostate symptom score and transitional prostate volume. Dostupný z http://onlinelibrary.wiley.com/doi/10.1111/luts.12150/full.

15. Meikle AW, Arver S, Dobs AS, et al. Prostate size in hypogonadal men treated with a nonscrotal permeation‑enhanced testosterone transdermal system. Urology. 1997; 49(2): 191-196.